Status:
ENROLLING_BY_INVITATION
Artificial Intelligence in New Cardiac MR Markers for Congenital Heart Disease
Lead Sponsor:
Sahlgrenska University Hospital
Conditions:
Aortic Valve Disease
Pulmonary Valve Disease
Eligibility:
All Genders
1-18 years
Brief Summary
The goal of this study is to investigate children with aortic and pulmonary valve disease treated or untreated longitudinally. Established CMR measures with additional newly developped, promising, hig...
Detailed Description
Background: An increasing number of children with complex congenital heart disease (CHD) are today treated and survive into adulthood. They are in need of a lifelong surveillance for cardiovascular c...
Eligibility Criteria
Inclusion
- aortic valve disease
- or pulmonary valve disease
- clinical indication for valvular surgery
- or clinical indication for valvular intervention
Exclusion
- contraindications for MRI
- need of sedation or general anesthesia, unless there is a clinical indication for a CMR
Key Trial Info
Start Date :
October 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2028
Estimated Enrollment :
45 Patients enrolled
Trial Details
Trial ID
NCT05979870
Start Date
October 1 2022
End Date
December 31 2028
Last Update
May 15 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Queen Silvia Children'sHospital, Sahlgrenska University Hospital
Gothenburg, Gothenburg, Sweden, 41560